Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
May 30, 2024 16:05 ET
|
Oncternal Therapeutics
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Celcuity Announces Pricing of Underwritten Common Stock Offering
May 30, 2024 07:36 ET
|
Celcuity Inc.
MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the...
Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing
May 30, 2024 07:00 ET
|
Celcuity Inc.
The Phase 3 clinical trial will evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer who are endocrine therapy...
Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update
May 15, 2024 16:01 ET
|
Celcuity Inc.
The Phase 3 VIKTORIA-1 trial remains on track to report topline data from PIK3CA wild type patient sub-group in the second half of 2024First patient dosed in a Phase 1b/2 clinical trial evaluating...
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
May 08, 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Orion Group Interim Report January–March 2024
April 25, 2024 05:00 ET
|
Orion Oyj
ORION CORPORATION INTERIM REPORT 1-3/2024 25 APRIL 2024 at 12:00 EEST Orion Group Interim Report January–March 2024 Net sales totalled EUR 308.5...
World Metastatic Prostate Cancer Drug Landscape Research Report 2024: Comprehensive Insights about 90+ Companies and 110+ Pipeline Drugs
April 18, 2024 09:11 ET
|
Research and Markets
Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Prostate Cancer - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
April 18, 2024 09:00 ET
|
Oncternal Therapeutics
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
April 04, 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 27, 2024 16:01 ET
|
Celcuity Inc.
Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical data...